Sep 17, 2026 09:11AM
Sep 17, 2026 09:10AM
Sep 9, 2026 04:15PM
Sep 8, 2026 08:02AM
Sep 8, 2026 08:00AM
Sep 4, 2026 09:20AM
Sep 1, 2026 09:15AM Lexaria receives $2.6M tax rebate from Australian R&D program
Sep 1, 2026 09:15AM
Aug 24, 2026 09:10AM
Aug 13, 2026 09:02AM
Aug 13, 2026 09:00AM
Jul 30, 2026 11:00AM
Jul 30, 2026 11:00AM
Jul 6, 2026 09:11AM Lexaria reports partner meetings at BIO convention in San Diego
Jul 6, 2026 09:10AM
Jun 25, 2026 09:10AM
Jun 23, 2026 09:25AM
Jun 17, 2026 09:25AM
Jun 9, 2026 09:25AM
Jun 9, 2026 09:25AM
Jun 3, 2026 09:25AM Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
May 19, 2026 09:15AM
May 7, 2026 09:25AM
May 5, 2026 09:11AM
May 5, 2026 09:10AM
May 1, 2026 09:25AM
Apr 29, 2026 09:10AM
Apr 29, 2026 09:10AM Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Apr 23, 2026 09:05AM
Apr 21, 2026 09:10AM
Apr 15, 2026 09:10AM
Apr 7, 2026 09:10AM
Apr 7, 2026 09:10AM
Apr 1, 2026 09:20AM
Apr 1, 2026 09:20AM Lexaria to Begin New Human Clinical Study in GLP-1
Mar 26, 2026 09:20AM
Mar 26, 2026 09:20AM
Mar 24, 2026 09:15AM
Mar 24, 2026 09:15AM
Mar 4, 2026 09:25AM
Mar 4, 2026 09:25AM
Feb 5, 2026 09:15AM Lexaria Announces Positive Final Results From Human Pilot Study #5
Jan 22, 2026 09:22AM
Jan 22, 2026 09:20AM
Jan 12, 2026 09:10AM
Jan 12, 2026 09:10AM
Dec 30, 2025 09:20AM
Dec 30, 2025 09:20AM
Dec 23, 2025 09:29AM Lexaria achieves primary endpoint in Phase 1b GLP-1 study
Dec 23, 2025 09:29AM

332,961 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All